Editorial: Spoilt? Pharma? Surely Some Mistake
This article was originally published in Scrip
Some people reckon that what others say of us is none of our business. It's a useful maxim for retaining sanity in the Twitter and Google age, but perhaps there are times when a bit of constructive criticism is good for the soul. We all know that the public perception of the pharma industry isn't great, but the opinions of an Ivy League economics professor laid out in a recent JAMA Forum commentary may sting. Paraphrasing, it seems Professor Uwe Reinhardt thinks you're a bit spoilt: fragile little birds shielded by government from the harsh realities of the free market, and enjoying monopoly positions. He's got a point.
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.